RTs (in ms, bars) and ACC (in%, line) across time points, with 95% confidence interval. by Marcel F. Hinss (14675457)

BT9 exhibits a dose- and time-dependent cytotoxic effect on medulloblastoma. by Zahra Motahari (6814013)

Modeled lichen species richness in a prediction grid from 0 to 4000 m from the DMTS haul road in Cape Krusenstern National Monument, Alaska. by Peter N. Neitlich (4034300)

Subjects:

Comparison of the decrease of CFU in CSF and blood between treatment groups within the first 6 h after treatment. by Luca G. Valente (12463057)

Means for global competence pre- and post-test scores. by Esther Kim (2996622)

DMSO solvent toxicity assay at different concentrations and cytotoxicity assay of DAM-1. by Manoj Limbraj Yellurkar (11467219)

Subjects:

The solution of recovered compartment of model (1) asymptotically approaches to the endemic equilibrium for the data (54), the solution is decreasing with increasing in value of <i... by Dilber Uzun Ozsahin (18320075)

Means and standard deviations of the age of mothers, fathers, and children across the seven waves. by Chiara Remondi (15301459)

MBIC50 and MBEC50 values (µg/mL) of synthesized 1,2,3,5-tetrazine derivatives against bacteria pathogen strains. by Jean Paul Dzoyem (6424445)

Subjects:

Fig 5 - by Evelyn Medawar (9774392)

Annual number of outpatient visits in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

“…<p>In the recurrence group, mean outpatient visits (± standard deviation) decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Annual treatment frequencies in all eyes. by Yasuyuki Sotani (20114144)

“…<p>The number of anti-VEGF treatments, STTA, MA-PC, PPV, and total treatments (mean ± SD) significantly decreased from 2.6 ± 1.6, 0.3 ± 0.8, 0.6 ± 0.8, 0.1 ± 0.3, and 3.7 ± 1.7 preoperatively to 0.8 ± 1.9, 0.0 ± 0.2, 0.3 ± 1.0, 0.0, and 1.2 ± 2.2; at year 2 to 0.7 ± 2.0, 0.1 ± 0.6, 0.0 ± 0.2, 0.0 ± 0.2, and 1.0 ± 2.1; and at year 3 to 0.9 ± 2.2, 0.0, 0.2 ± 1.0, 0.0 ± 0.2, and 1.1 ± 3.1 (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Annual treatment frequencies in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

“…Mean outpatient visits in the recurrence group decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, p < 0.001). …”

Exercise testing criteria to diagnose lower extremity peripheral artery disease assessed by computed-tomography angiography by O. Stivalet (6890189)

“…The receiver-operating-characteristic curve was used to define a cut-off point corresponding to the best area under the curve (AUC; [CI95%]) to detect arterial stenosis ≥50% as determined by the CTA.…”

NRX-1 localization to cholinergic axons is decreased in <i>unc-104</i> mutants and colocalizes with UNC-104 in cholinergic axon terminals. by Devyn Oliver (12015660)

Estimated mean lichen species richness vs. distance to the DMTS haul road in Cape Krusenstern National Monument, Alaska, on a log-log scale from a Bayesian posterior predictions mo... by Peter N. Neitlich (4034300)

Subjects:

The human neutrophil IL-1β secretory response, in contrast to the CXCL8/IL-8 secretory response decreases as MOI increases. by Florencia Sabbione (4862455)

Differential gene expression assay EC₅₀ values in Huh-7 cells and PHH. by Xuan G. Luong (9761423)

Presentation_1_Airway macrophages display decreased expression of receptors mediating and regulating scavenging in early cystic fibrosis lung disease.pdf by Lisa J. M. Slimmen (16464600)

“…The effect of age and neutrophilic inflammation, among other variables, on marker expression was assessed with a multivariate linear regression model.</p>Results<p>AM expression of scavenger receptor CD163 decreased with age (p = 0.016) and was negatively correlated with BALF %neutrophils (r = -0.34, p = 0.016). …”

Differential protective effects of a history of thyroid cancer on breast cancer-specific mortality in patients at age<50years and age≥50years at the diagnosis of breast cancer. by Weiwei Cheng (582223)